Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101635775> ?p ?o ?g. }
- W2101635775 endingPage "5797" @default.
- W2101635775 startingPage "5790" @default.
- W2101635775 abstract "Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL. Current frontline therapy for CML is imatinib, an inhibitor of BCR-ABL. Although imatinib has a high rate of clinical success in early phase CML, treatment resistance is problematic, particularly in later stages of the disease, and is frequently mediated by mutations in BCR-ABL. Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets oncogenic pathways and is a more potent inhibitor than imatinib against wild-type BCR-ABL. It has also shown preclinical activity against all but one of the imatinib-resistant BCR-ABL mutants tested to date. Analysis of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of dasatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL. The structure also provides an explanation for the activity of dasatinib against imatinib-resistant BCR-ABL mutants." @default.
- W2101635775 created "2016-06-24" @default.
- W2101635775 creator A5002124900 @default.
- W2101635775 creator A5021559510 @default.
- W2101635775 creator A5027980862 @default.
- W2101635775 creator A5030635704 @default.
- W2101635775 creator A5042712453 @default.
- W2101635775 creator A5043856025 @default.
- W2101635775 creator A5052039233 @default.
- W2101635775 creator A5056681722 @default.
- W2101635775 creator A5059226795 @default.
- W2101635775 creator A5079221001 @default.
- W2101635775 creator A5084550335 @default.
- W2101635775 creator A5086322094 @default.
- W2101635775 creator A5086676382 @default.
- W2101635775 date "2006-06-01" @default.
- W2101635775 modified "2023-10-16" @default.
- W2101635775 title "The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants" @default.
- W2101635775 cites W1539796472 @default.
- W2101635775 cites W1543269083 @default.
- W2101635775 cites W1972441201 @default.
- W2101635775 cites W1973720500 @default.
- W2101635775 cites W1992945955 @default.
- W2101635775 cites W1995017064 @default.
- W2101635775 cites W1999614615 @default.
- W2101635775 cites W2001641653 @default.
- W2101635775 cites W2006917576 @default.
- W2101635775 cites W2015616444 @default.
- W2101635775 cites W2033444434 @default.
- W2101635775 cites W2040381937 @default.
- W2101635775 cites W2041415161 @default.
- W2101635775 cites W2057069307 @default.
- W2101635775 cites W2066998725 @default.
- W2101635775 cites W2076372887 @default.
- W2101635775 cites W2078412962 @default.
- W2101635775 cites W2080476827 @default.
- W2101635775 cites W2092606584 @default.
- W2101635775 cites W2095226581 @default.
- W2101635775 cites W2097946794 @default.
- W2101635775 cites W2101214437 @default.
- W2101635775 cites W2101390452 @default.
- W2101635775 cites W2118460316 @default.
- W2101635775 cites W2122109248 @default.
- W2101635775 cites W2123940645 @default.
- W2101635775 cites W2130479394 @default.
- W2101635775 cites W2131067167 @default.
- W2101635775 cites W2131174104 @default.
- W2101635775 cites W2135429827 @default.
- W2101635775 cites W2157277269 @default.
- W2101635775 cites W2161835431 @default.
- W2101635775 cites W2171722798 @default.
- W2101635775 cites W2312804644 @default.
- W2101635775 cites W2329648702 @default.
- W2101635775 cites W2550859769 @default.
- W2101635775 cites W2570622505 @default.
- W2101635775 cites W2575086792 @default.
- W2101635775 cites W2579376724 @default.
- W2101635775 cites W2975250779 @default.
- W2101635775 cites W2994484228 @default.
- W2101635775 cites W4229643409 @default.
- W2101635775 doi "https://doi.org/10.1158/0008-5472.can-05-4187" @default.
- W2101635775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16740718" @default.
- W2101635775 hasPublicationYear "2006" @default.
- W2101635775 type Work @default.
- W2101635775 sameAs 2101635775 @default.
- W2101635775 citedByCount "581" @default.
- W2101635775 countsByYear W21016357752012 @default.
- W2101635775 countsByYear W21016357752013 @default.
- W2101635775 countsByYear W21016357752014 @default.
- W2101635775 countsByYear W21016357752015 @default.
- W2101635775 countsByYear W21016357752016 @default.
- W2101635775 countsByYear W21016357752017 @default.
- W2101635775 countsByYear W21016357752018 @default.
- W2101635775 countsByYear W21016357752019 @default.
- W2101635775 countsByYear W21016357752020 @default.
- W2101635775 countsByYear W21016357752021 @default.
- W2101635775 countsByYear W21016357752022 @default.
- W2101635775 countsByYear W21016357752023 @default.
- W2101635775 crossrefType "journal-article" @default.
- W2101635775 hasAuthorship W2101635775A5002124900 @default.
- W2101635775 hasAuthorship W2101635775A5021559510 @default.
- W2101635775 hasAuthorship W2101635775A5027980862 @default.
- W2101635775 hasAuthorship W2101635775A5030635704 @default.
- W2101635775 hasAuthorship W2101635775A5042712453 @default.
- W2101635775 hasAuthorship W2101635775A5043856025 @default.
- W2101635775 hasAuthorship W2101635775A5052039233 @default.
- W2101635775 hasAuthorship W2101635775A5056681722 @default.
- W2101635775 hasAuthorship W2101635775A5059226795 @default.
- W2101635775 hasAuthorship W2101635775A5079221001 @default.
- W2101635775 hasAuthorship W2101635775A5084550335 @default.
- W2101635775 hasAuthorship W2101635775A5086322094 @default.
- W2101635775 hasAuthorship W2101635775A5086676382 @default.
- W2101635775 hasBestOaLocation W21016357751 @default.
- W2101635775 hasConcept C104317684 @default.
- W2101635775 hasConcept C121608353 @default.
- W2101635775 hasConcept C125418893 @default.
- W2101635775 hasConcept C126322002 @default.
- W2101635775 hasConcept C143065580 @default.